glp 1 research Discovery of GLP-1–Based Drugs for the Treatment of Obesity Frontiers | Exploring the multifaceted
Description
Statistical tools included SPSS and meta-analysis software for pooled estimates
Government initiatives like the salt reduction programme in the 2000s initially worked, but progress on sugar and calorie reduction has stalled
Phase 3 REDEFINE trials confirmed 50% greater weight loss compared to semaglutide alone, with 43% of participants achieving over 20% body weight loss
If hormonal deficiency was also a factor, that underlying issue would still need to be addressed separately
However, multiple forces are converging to limit their future: 1
